GSK markets Flulaval as “a vaccine indicated for active immunization disease”; however does not indicate that the vaccine is effectual.

According to the insert for Flulaval, “there have been no controlled trials adequately demonstrating a decrease in influenza disease after vaccination with” this product.

Another shocking confession about Flulaval by GSK is that the vaccine has “not been evaluated for carcinogenic or mutagenic potential, [and] impairment of fertility” along with the fact that “safety and effectiveness of Flulaval in pediatric patients [has] not been established” which includes:

The 2014-2015 flu season hit a snag in treatment options with “effectiveness of the vaccine only 25%, while it was 50-60% during other years” according to the Centers for Disease Control and Prevention (CDC).

The current strain of flu “attacking” people is H3N2 which is believed to have “mutated from the earlier strain”.

Vaccines available to the public is only 25% effective at combating H3N2, however doctors are recommending it as prevention – better than nothing at all.